ZHAO Zhen 1,2 , WU Yan 1,2 , LIN Rongruo 1,2 , YANG Hongzhao 1,2 , WANG Xiaodong 1,2 , LI Li 1,2
  • 1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 2. West China School of Medicine in Sichuan University, Chengdu 610041, P. R. China;
LI Li, Email: drlili116@126.com
age; colorectal cancer; neoadjuvant therapy; Database from Colorectal Cancer
10.7507/1007-9424.202205020
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To analyze the relation between the age of patients with colorectal cancer and neoadjuvant therapy (NAT) regimen decision-making and outcomes in the current version of the Database from Colorectal Cancer (DACCA). Methods The version of DACCA selected for this analysis was updated on January 5, 2022. The patients were enrolled according to the established screening criteria and then assigned to 3 age groups: ≤45, 45–65, and ≥65 years old groups. The differences in the NAT regimen decision-making and changes of symptom, imaging, and cancer markers in these 3 age groups were analyzed. Results A total of 4 882 data that met the screened criteria were enrolled. The results of statistical analysis showed that the difference in the constituent ratio of patients chosen NAT strategies among 3 age groups was not statistically significant (χ2=8.885, P=0.180). There was a statistical difference in the constituent ratio of patients chosen combined target drug among 3 age groups (χ2=8.530, P=0.014), it was found that the proportion of the patients with ≤45 years old adopting combined target drug regimen was higher. Although the changes of symptom (H=12.299, P=0.056), image (H=1.775, P=0.412), and cancer markers (H=11.351, P=0.183) had no statistical differences of the 3 age groups after NAT, it was found that the proportions of patients with ≥65 years old with progresses of symptom and imaging changes and elevated cancer markers after NAT were higher, and the proportions of patients with ≤45 years old with complete and partial remissions of symptom and imaging changes and with normal cancer markers after NAT were higher. Conclusions Through analysis of DACCA data, it is found that in the selection of NAT strategy for colorectal cancer, the lower age group, the higher proportion of patients adopting combined target drug regimen. Although it is not found that age is related to changes of symptoms, imaging, and cancer markers after NAT, it still shows a trend of better outcomes in younger patients.

Citation： ZHAO Zhen, WU Yan, LIN Rongruo, YANG Hongzhao, WANG Xiaodong, LI Li. Relation between age of patients with colorectal cancer and decision-making and treatment effect of neoadjuvant regimens: a real-world study based on DACCA. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(7): 946-950. doi: 10.7507/1007-9424.202205020 Copy

  • Previous Article

    甲状腺/甲状旁腺术后早期低钙血症诱发的清醒状态下喉痉挛2例报道

  • Next Article

    乳腺癌合并肺结核治疗1例报道